Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9%…
QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an…